title: What's next in translational medicine?
abstract: Translational medicine is the integrated application of innovative pharmacology tools, biomarkers, clinical methods, clinical technologies and study designs to improve disease understanding, confidence in human drug targets and increase confidence in drug candidates, understand the therapeutic index in humans, enhance cost-effective decision making in exploratory development and increase phase II success. Translational research is one of the most important activities of translational medicine as it supports predictions about probable drug activities across species and is especially important when compounds with unprecedented drug targets are brought to humans for the first time. Translational research has the potential to deliver many practical benefits for patients and justify the extensive investments placed by the private and public sector in biomedical research. Translational research encompasses a complexity of scientific, financial, ethical, regulatory, legislative and practical hurdles that need to be addressed at several levels to make the process efficient. Several have resisted the idea of supporting translational research because of its high costs and the fear that it may re-direct funds from other biomedical disciplines. Resistance also comes from those more familiar with traditional clinical research methods. In this review, we argue that translational research should be seen as enabled by ongoing efforts in basic and clinical research and not competing with them. Translational research provides the knowledge necessary to draw important conclusions from clinical testing regarding disease and the viability of novel drug mechanisms. Advancing translational research requires education and new sources of funding. This could be achieved through public and congressional education by a joint coalition of patients' advocacy groups, academia, drug regulatory agencies and industry.
authors.affiliation: Global Translational Medicine, Pfizer Global Research and Development, Pfizer Inc, New London, CT 23240, USA.
authors.forename: Bruce H
authors.initials: BH
authors.lastname: Littman
authors.forename: Linda
authors.initials: L
authors.lastname: Di Mario
authors.forename: Mario
authors.initials: M
authors.lastname: Plebani
authors.forename: Francesco M
authors.initials: FM
authors.lastname: Marincola
mesh_terms: D000818:Animals; D035843:Biomedical Research / Q000191:economics / Q000639:trends*; D002626:Chemistry, Pharmaceutical / Q000639:trends*; D004341:Drug Evaluation / Q000191:economics; D004345:Drug Industry; D006801:Humans; D011639:Public Opinion; D012109:Research Support as Topic